Stocks and Investing
Stocks and Investing
Fri, March 15, 2013
[ Fri, Mar 15th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - Market Wire
[ Fri, Mar 15th 2013
] - Market Wire
[ Fri, Mar 15th 2013
] - Market Wire
[ Fri, Mar 15th 2013
] - Market Wire
[ Fri, Mar 15th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
David Amsellem Maintained (SUPN) at Buy with Decreased Target to $14 on, Mar 15th, 2013
David Amsellem of Piper Sandler, Maintained "Supernus Pharmaceuticals, Inc." (SUPN) at Buy with Decreased Target from $15 to $14 on, Mar 15th, 2013.
David has made no other calls on SUPN in the last 4 months.
There is 1 other peer that has a rating on SUPN. Out of the 1 peers that are also analyzing SUPN, 0 agree with David's Rating of Hold.
This is the rating of the analyst that currently disagrees with David
- David Steinberg of "Jefferies" Initiated at Strong Buy and Held Target at $13 on, Tuesday, March 5th, 2013
Contributing Sources
Similar Stocks and Investing Articles
[ Tue, Mar 12th 2013
] - WOPRAI
[ Tue, Mar 05th 2013
] - WOPRAI
[ Wed, Nov 14th 2012
] - WOPRAI
[ Wed, Jul 18th 2012
] - WOPRAI
[ Mon, Jul 16th 2012
] - WOPRAI
[ Wed, May 23rd 2012
] - WOPRAI
[ Tue, May 01st 2012
] - WOPRAI
[ Wed, Apr 25th 2012
] - WOPRAI
[ Wed, Apr 25th 2012
] - WOPRAI
[ Tue, Mar 27th 2012
] - WOPRAI